The relation between intermittent dosing and adherence: Preliminary insights

Clinical Therapeutics

Volumn 28, Issue 12, 2006, Pages 1989-1995

  Kruk, Margaret E ^a   Schwalbe, Nina ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

intermittent dosing, patient adherence, dose frequency

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; FLUOXETINE; GESTAGEN; MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT; RISEDRONIC ACID; SERTRALINE;

CLINICAL TRIAL; COMPARATIVE STUDY; CONTRACEPTION; DEPRESSION; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; HUMAN; MEDLINE; MENOPAUSAL SYNDROME; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; PATIENT COMPLIANCE; PREMENSTRUAL DYSPHORIC DISORDER; REVIEW;

CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACEUTICAL PREPARATIONS;

EID: 33846840781     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.12.011     Document Type: Review

References (17)

1. Bender B.G., and Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 4 (2004) 191-195
2. Balkrishnan R., Rajagopalan R., Camacho F.T., et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study. Clin Ther 25 (2003) 2958-2971
3. Knapp M., King D., Pugner K., and Lapuerta P. Non-adherence to antipsychotic medication regimens: Associations with resource use and costs. Br J Psychiatry 184 (2004) 509-516
4. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 23 (2001) 1296-1310
5. [published correction appears in JAMA. 1989;262: 1472]. Cramer J.A., Mattson R.H., Prevey M.L., et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 261 (1989) 3273-3277
6. discussion 2306. Richter A., Anton S.E., Koch P., and Dennett S.L. The impact of reducing dose frequency on health outcomes. Clin Ther 25 (2003) 2307-2335
7. Claxton A., de Klerk E., Parry M., et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 61 (2000) 928-932
8. Archer D.F., Bigrigg A., Smallwood G.H., et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 77 Suppl 2 (2002) S27-S31
9. Recker R.R., Gallagher R., and MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80 (2005) 856-861
10. Burke W.J., Hendricks S.E., McArthur-Miller D., et al. Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: Results from a placebo-controlled, randomized clinical trial. J Clin Psychopharmacol 20 (2000) 423-427
11. Erenus M., Karakoc B., and Gurler A. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric. 4 (2001) 228-234
12. Oddsson K., Leifels-Fischer B., de Melo N.R., et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: A 1-year randomized trial. Contraception 71 (2005) 176-182
13. Freeman E.W., Rickels K., Sondheimer S.J., et al. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 161 (2004) 343-351
14. Weisberg F., Bouchard C., Moreau M., et al., NRGEEP-CON-401 Study Group. Preference for and sat isfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: An open-label, multicentre study. J Obstetr Gynaecol Can 27 (2005) 350-359
15. Weiss M., Vered I., Foldes A.J., et al., Israeli Alendronate OW Study Group. Treatment preference and tolerability with alendronate once weekly over a 3-month period: An Israel multi-center study. Aging Clin Exp Res 17 (2005) 143-149
16. Simon J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for once weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, openlabel, crossover study. Clin Ther 24 (2002) 1871-1886
17. Kendler D., Kung A.W., Fuleihan G.-H., et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48 (2004) 243-251